Neoadjuvant HER2+

>

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Latest News

Debu Tripathy, MD
HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

March 10th 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

HER2-Positive Breast Cancer
T-DXd Has Intracranial Activity in Meta-Analysis of HER2+ Breast Cancer Brain Metastases

March 8th 2024

stock.adobe.com
T-DXd Fails to Receive Recommendation From NICE for HER2-Low Breast Cancer Treatment

March 6th 2024

Sarah Sammons, MD, of Dana-Farber Cancer Institute
Sammons Spotlights Approaches Under Exploration for HER2+ Breast Cancer and Brain Metastases

February 19th 2024

Sarah Sammons, MD, associate director, the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute
Real-World Analysis Sheds Light on Brain Metastases Incidence in HER2+ Breast Cancer

February 15th 2024

Video Series
Video Interviews
Podcasts
Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer

More News